Brief: Nabriva Therapeutics completes patient enrollment in Phase 1 Trial of Xenleta® (Lefamulin) in adult patients with cystic fibrosis
11/08/2022 12:25
Aug 11 (Reuters) - Nabriva Therapeutics PLC NBRV.O :
* NABRIVA THERAPEUTICS COMPLETES PATIENT ENROLLMENT IN PHASE
1
TRIAL OF XENLETA® (LEFAMULIN) IN ADULT PATIENTS WITH CYSTIC
FIBROSIS
* NABRIVA THERAPEUTICS PLC - EXPECT TO REPORT TOPLINE DATA
IN Q1
OF 2023
Source text for Eikon: ID:nGNX2ZfLzH
Further company coverage: NBRV.O
Recent news on Nabriva Therapeutics
See all newsBrief: Nabriva Therapeutics And Units Enter Asset Purchase Agreement With Sumitomo Pharma
Brief: Nabriva Therapeutics Says Received Delisting Determination Letter From Nasdaq
Brief: Nabriva Therapeutics Receives Notice Of Delisting Or Failure To Satisfy Continued Listing Rule From Nasdaq
Brief: Nabriva Therapeutics - On Jan 31, Co's Unit Entered Into Letter Agreement With 2 Units Of Merck & Co, About Distribution Agreement, Dated July 15, 2020
Brief: Nabriva Therapeutics Provides Corporate Update